Literature DB >> 29391233

Effects of Qijian mixture on type 2 diabetes assessed by metabonomics, gut microbiota and network pharmacology.

Kuo Gao1, Ran Yang2, Jian Zhang3, Zhiyong Wang4, Caixia Jia5, Feilong Zhang6, Shaojing Li7, Jinping Wang8, Ghulam Murtaza9, Hua Xie10, Huihui Zhao11, Wei Wang12, Jianxin Chen13.   

Abstract

Qijian mixture, a new traditional Chinese medicine (TCM) formula comprising of Astragalus membranaceus, Ramulus euonymi, Coptis chinensis and Pueraria lobata, was designed to ameliorate the type 2 diabetes (T2D), and its safety and efficacy were evaluated in the research by metabonomics, gut microbiota and system pharmacology. To study the hypoglycemic effect of Qijian mixture, male KKay mice (28-30 g, 8-9 week) and C57/BL6 mice (18-19 g, 8-9 week) were used. Thirty KKay diabetic mice were randomly distributed into 5 groups, abbreviated as Model group (Model), Low Qijian Mixture group (QJM(L)), High Qijian Mixture group (QJM(H)), Chinese Medicine (Gegen Qinlian Decoction) Positive group (GGQL), and Western Medicine (Metformin hydrochloride) Positive group (Metformin). C57/BL6 was considered as the healthy control group (Control). Moreover, a system pharmacology approach was utilized to assess the physiological targets involved in the action of Qijian mixture. There was no adverse drug reaction of Qijian mixture in the acute toxicity study and HE result, and, compared with Model group, Qijian mixture could modulate blood glycemic level safely and effectively. Qijian Mixture was lesser effective than metformin hydrochloride; however, both showed similar hypoglycemic trend. Based on 1H NMR based metabonomics study, the profoundly altered metabolites in Qijian mixture treatment group were identified. Qijian mixture-related 55 proteins and 4 signaling pathways, including galactose metabolism, valine, leucine and isoleucine degradation metabolism, aminoacyl-tRNA biosynthesis metabolism and alanine, aspartate and glutamate metabolism pathways, were explored. The PCoA analysis of gut microbiota revealed that Qijian mixture treatment profoundly enriched bacteroidetes. In addition, the system pharmacology paradigm revealed that Qijian mixture acted through TP53, AKT1 and PPARA proteins. It was concluded that Qijian mixture effectively alleviated T2D, and this effect was linked with the altered features of the metabolite profiles and the gut microbiota.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Gut microbiota; Mechanism of action; Metabonomics; Molecular targets; System pharmacology; Type 2 diabetes

Mesh:

Substances:

Year:  2018        PMID: 29391233     DOI: 10.1016/j.phrs.2018.01.011

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  20 in total

1.  Metformin elicits antitumour effect by modulation of the gut microbiota and rescues Fusobacterium nucleatum-induced colorectal tumourigenesis.

Authors:  Xiaowen Huang; Xialu Hong; Jilin Wang; Tiantian Sun; TaChung Yu; Yanan Yu; Jingyuan Fang; Hua Xiong
Journal:  EBioMedicine       Date:  2020-10-09       Impact factor: 8.143

2.  An Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhong Pill for Treating Diarrhea-Predominant Irritable Bowel Syndrome.

Authors:  Zhang Zhen; Lin Xia; Huang You; Zhou Jingwei; Yang Shasha; Wei Xinyi; Lai Wenjing; Zhang Xin; Fu Chaomei
Journal:  Front Pharmacol       Date:  2021-11-30       Impact factor: 5.810

3.  The potential mechanism of Liu-Wei-Di-Huang Pills in treatment of type 2 diabetic mellitus: from gut microbiota to short-chain fatty acids metabolism.

Authors:  Zi-Yang Yi; Lin Chen; Yan Wang; Dan He; Di Zhao; Shui-Han Zhang; Rong Yu; Jian-Hua Huang
Journal:  Acta Diabetol       Date:  2022-07-20       Impact factor: 4.087

4.  An Integrated Fecal Microbiome and Metabolomics in T2DM Rats Reveal Antidiabetes Effects from Host-Microbial Metabolic Axis of EtOAc Extract from Sophora flavescens.

Authors:  Jing Shao; Yi Liu; Huan Wang; Yun Luo; Lei Chen
Journal:  Oxid Med Cell Longev       Date:  2020-05-27       Impact factor: 6.543

5.  Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico and experimental study.

Authors:  Ruocong Yang; Hao Liu; Chen Bai; Yingchao Wang; Xiaohui Zhang; Rui Guo; Siying Wu; Jianxun Wang; Elaine Leung; Hang Chang; Peng Li; Tiegang Liu; Yi Wang
Journal:  Pharmacol Res       Date:  2020-04-29       Impact factor: 7.658

6.  Integrating Pharmacology and Microbial Network Analysis with Experimental Validation to Reveal the Mechanism of Composite Sophora Colon-Soluble Capsule against Ulcerative Colitis.

Authors:  Yuxuan Ding; Mingjun Chen; Qiying Wang; Lu Gao; Yang Feng; Shida Wang; Zitian Song; Zhanqi Tong
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-20       Impact factor: 2.629

7.  Considering gut microbiota in treatment of type 2 diabetes mellitus.

Authors:  Aneseh Adeshirlarijaney; Andrew T Gewirtz
Journal:  Gut Microbes       Date:  2020-01-31

Review 8.  Alzheimer's Disease and Diabetes: Role of Diet, Microbiota and Inflammation in Preclinical Models.

Authors:  Maria Jose Carranza-Naval; Maria Vargas-Soria; Carmen Hierro-Bujalance; Gloria Baena-Nieto; Monica Garcia-Alloza; Carmen Infante-Garcia; Angel Del Marco
Journal:  Biomolecules       Date:  2021-02-10

Review 9.  Effects of Metformin on the Gut Microbiota in Obesity and Type 2 Diabetes Mellitus.

Authors:  Qi Zhang; Nan Hu
Journal:  Diabetes Metab Syndr Obes       Date:  2020-12-16       Impact factor: 3.168

Review 10.  Role of gut microbiota in identification of novel TCM-derived active metabolites.

Authors:  Tzu-Lung Lin; Chia-Chen Lu; Wei-Fan Lai; Ting-Shu Wu; Jang-Jih Lu; Young-Mao Chen; Chi-Meng Tzeng; Hong-Tao Liu; Hong Wei; Hsin-Chih Lai
Journal:  Protein Cell       Date:  2020-09-15       Impact factor: 14.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.